Table 1.
Characteriscs of study participants in the placebo arm of PCPT and results from univariate analyses
| Variables | Entire cohort | Men with a positive FH | Men with a negative FH | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
|
|
||||||||||
| PCa (N=1104) |
Non-PCa (N=3424) |
OR (95% CI) | P | PCa (N=224) |
Non-PCa (N=548) |
OR (95% CI) | P | PCa (N=880) |
Non-PCa (N=2876) |
OR (95% CI) | P | |
| Age, mean, year | 63.74 | 62.82 | 1.03(1.02–1.04) | 1.25E-06 | 62.9 | 62.32 | 1.02(0.99–1.05) | 1.89E-01 | 63.96 | 62.91 | 1.04(1.02–1.05) | 8.27E-07 |
| tPSA, median, ng/mL | 1.40 | 1.00 | 2.11(1.88–2.37) | 8.96E-36 | 1.40 | 1.10 | 1.85(1.41–2.42) | 8.86E-06 | 1.40 | 1.00 | 2.16(1.90–2.46) | 3.75E-31 |
| DRE, # (%) positive | 15.86 | 4.49 | 4.01(3.17–5.06) | 2.41E-31 | 15.98 | 4.44 | 4.10(2.34–7.17) | 7.86E-07 | 15.83 | 4.50 | 3.99(3.08–5.16) | 6.69E-26 |
| FH, # (%) positive | 20.29 | 16.00 | 1.34(1.12–1.59) | 1.02E-03 | ||||||||
| GRS, median | 1.08 | 0.87 | 1.49(1.37–1.62) | 1.46E-19 | 1.15 | 0.92 | 1.57(1.25–1.97) | 1.18E-04 | 1.05 | 0.85 | 1.47(1.34–1.61) | 4.50E-16 |
PCPT: Prostate Cancer Prevention Trial
PCa: Prostate cancer
tPSA: Total prostate-specific antigen
DRE: Digital rectal examination
FH: Family history
GRS: Genetic risk score